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The second messenger molecule 3’5’-cyclic adenosine monophosphate (cAMP) imparts 43 
several beneficial effects in lung diseases such as asthma, chronic obstructive pulmonary 44 
disease (COPD) and idiopathic pulmonary fibrosis (IPF).  While cAMP is bronchodilatory in 45 
asthma and COPD, it also displays anti-fibrotic properties that limit fibrosis. 46 
Phosphodiesterases (PDEs) metabolize cAMP and thus regulate cAMP signaling. While 47 
some existing therapies inhibit PDEs, there are only broad family-specific inhibitors. The 48 
understanding of cAMP signaling compartments, some centered around lipid 49 
rafts/caveolae, has led to interest in defining how specific PDE isoforms maintain these 50 
signaling microdomains. The possible altered expression of PDEs, and thus abnormal 51 
cAMP signaling, in obstructive lung diseases has been poorly explored.  We propose that 52 
inhibition of specific PDE isoforms can improve therapy of obstructive lung diseases by 53 
amplifying specific cAMP signals in discreet microdomains.  54 






Chronic obstructive pulmonary disease (COPD), asthma and idiopathic pulmonary 57 
fibrosis (IPF) represent leading causes of morbidity and mortality [1-3].  These diseases 58 
are characterized by airway obstruction, chronic inflammation and airway remodeling, 59 
though the extent of each component varies by disease.  Airway obstruction leading to a 60 
shortness of breath is a common feature of COPD, asthma and IPF.  In asthma, such 61 
obstruction is associated with airway hyperresponsiveness but in all three diseases 62 
bronchodilators are used to open the airways [4].  Inflammation in COPD is characterized 63 
by increased numbers of CD8+ T-lymphocytes, macrophages and neutrophils, while in 64 
asthma inflammation is characterized by eosinophils, CD4+ T-lymphocytes and mast cells 65 
[4]. The asthma-COPD disease overlap syndrome (ACOS) adds another level of 66 
complexity representing disease phenotypes.  For example, severe asthmatics can display 67 
increased numbers of neutrophils and COPD patients suffering from exacerbations 68 
typically have increased numbers of eosinophils.  These circumstances make it a major 69 
challenge to manage the therapy of patients with ACOS. [5].  70 
In the etiology of IPF, the role of inflammation is disputed and largely considered a 71 
by-product of fibrosis [3,6,7].  Since anti-inflammatory treatments show minimal therapeutic 72 
benefit in patients with IPF, research has shifted focus to viewing the diesease as a defect 73 
in the healing and repair process with concomitant inflammation [6].  Upon alveolar 74 
epithelial injury, transforming growth factor (TGF)-β induces fibroblast cells to transition 75 
into -smooth muscle actin expressing myofibroblasts, which produce excess collagen and 76 
extracellular matrix proteins [8].  Due to continuous alveolar epithelial microinjury, a 77 
dysregulated response occurs where myofibroblasts persist and remain active for an 78 





alveolar epithelial type I cells are damaged, alveolar epithelial type II cells regenerate the 80 
damage [11].  Abnormal healing responses causes an inability of alveolar epithelial type II 81 
cells to regenerate epithelial cells leading to permanent loss of functional lung tissue [12]. 82 
All these obstructive lung diseases are caused by a diverse subset of genetic and 83 
environmental factors including allergens, cigarette smoke and air pollution [13].  Air 84 
pollution emanating from primarily diesel automotive engines is linked to metabolic 85 
dysregulation, metabolic reprogramming, and mitochondrial dysfunction in each disorder 86 
[14-16].  Taken together, these three represent serious pulmonary diseases that possess 87 
both common and unique characteristics.  The heterogenous nature of these obstructive 88 
lung disorders hinders an effective treatment of all patient groups.  New therapies tailored 89 
to the heterogeneity of the patient cohorts need to be developed based on novel insights 90 
that integrate underlying molecular mechanisms into translational pharmacological 91 
research.  3’5’-cyclic adenosine monophosphate (cAMP) acts as a key regulator of all cells 92 
in the body.  In the lung, cAMP regulates airway smooth muscle tone, cell proliferation, 93 
differentiation, apoptosis, inflammatory mediator synthesis and release, deposition of 94 
extracellular matrix, and the maintenance of barrier function in both endothelial and 95 
epithelial cells [17,18].  In this review, we will discuss multi-component therapies based on 96 
the concept of compartmentalization of cellular cAMP signaling pathways with a focus on 97 
strategies that target phosphodiesterases (PDEs). 98 
 99 
Limitations of current treatment guidelines 100 
The extent of airway obstruction, chronic inflammation and airway remodeling varies 101 
in COPD, asthma and IPF [1-3], resulting in disease specific treatment guidelines.  In the 102 





bronchodilators (β2-adrenoceptor (β2AR) agonists, anticholinergics and broad PDE 104 
inhibitors), and a combination therapies of inhaled corticosteroid plus long-acting β2-AR 105 
agonists or anticholinergics and long-acting β2-AR agonists.  The broad PDE4 inhibitor, 106 
roflumilast, has been approved as add-on treatment to these therapies in patients with 107 
severe COPD associated with bronchitis and a history of frequent exacerbations [1,19].  In 108 
the treatment and management of asthma, combined therapies of (short-acting or long-109 
acting) β2AR agonists and inhaled corticosteroid are primarily used.  Orally administered 110 
roflumilast has been proposed as a beneficial add-on therapy for use in patients with 111 
moderate-to-severe asthma but is not currently approved for this use [2,4,19].  112 
Theophylline, a broad-spectrum PDE inhibitor and adenosine receptor antagonist, has 113 
fallen out of favor for asthma maintenance due to a wide array of off-target effects.   114 
The treatment of IPF primarily relies on current anti-fibrotic therapeutics such as 115 
pirfenidone and nintedanib, both considered to have anti-inflammatory and anti-fibrotic 116 
action [3,6,7].  Importantly, it has been reported recently that Gs-coupled receptors such 117 
as the β2-AR and receptors for prostaglandin E2 (PGE2) are repressed in IPF lungs  [20-118 
22].  Therapies targeting receptors coupled to cAMP in lung fibroblasts have some degree 119 
of specificity based on more limited expression of receptors across lung cell types.  120 
However, no therapeutic strategy currently exploits the antifibrotic effects of cAMP.   121 
It has long been recognized that ß2AR agonists, and the receptors themselves, 122 
contribute to asthma mortality [23,24].  These findings have led many to discount the 123 
therapeutic potential of cAMP signaling due to its association with ß2AR as their canonical 124 
second messenger.  However, some of these adverse effects of ß2AR can be attributed to 125 





particularly in combination with ß2AR agonists, is a logical means to increase cAMP-127 
induced bronchodilation without enhancing maladaptive ß-arrestin signaling.   128 
A current limitation is existing PDE inhibitors lack specificity due to the broad 129 
expression patterns of PDE isoforms (Table 1 and Figure 1).  Expression and function of 130 
phosphodiesterases (primarily PDE4 and PDE3) are altered in lung pathologies, 131 
particularly upon cigarette smoke exposure [26,27].  As it is now well established that 132 
increasing cAMP can improve lung dysfunction [4,17-19], constraining the endogenous 133 
enzymes that degrade cAMP could have profound impact on the treatment of obstructive 134 
lung diseases.  Current cyclic nucleotide-based therapies induce broad effects through 135 
their action on many cell types, including airway smooth muscle, (myo)fibroblasts, 136 
bronchial epithelium and endothelium, and via inhibition of broad classes of PDE.  137 
Systemic or inhaled administration targets widely expressed proteins to induce therapeutic 138 
effects and unwanted side effects (Figure 1).  These cyclic nucleotide-based therapies 139 
neglect the impact of spatio-temporal dynamics of cAMP signaling and lead to global 140 
(many cells and tissues) and bulk (many subcellular domains) elevations of cAMP.  141 
However, research over the past 15 years pointed to the existence of cAMP-sensing 142 
multiprotein complexes composed of a distinct subset of cAMP-producing receptors and 143 
PDEs, leading to the accepted concept of compartmentalized cyclic nucleotide signalling 144 
[4,17-19].  Intriguingly, recent studies in human fibroblasts from IPF patients illustrate the 145 
importance of monitoring the kinetics and localization of intracellular cAMP signals [28,29].  146 
We will highlight some key findings of how the understanding of cAMP signaling 147 
compartments have evolved substantially, emphasizing the fact that no therapies yet exist 148 






The role of PDEs in compartmentized cAMP signaling 151 
cAMP signaling compartments were first proposed by Buxton and Brunton based on 152 
early observations of disparate effects of cAMP signals in cells [30].  G protein-coupled 153 
receptors (GPCRs) initiate the signaling cascade leading to second messenger generation 154 
and their localization in plasma membrane microdomains are critical elements in the 155 
subsequent localization of a cAMP signal [31].  The G protein, Gs, appears to be 156 
expressed uniformly across membrane microdomains and is in stoichiometric excess of 157 
both GPCRs and adenylyl cyclases (AC) [32].  AC isoforms reside in caveolar/lipid raft 158 
microdomains or in non-raft plasma membrane domains [31].  However, the generation of 159 
an intracellular signal in a microdomain losses its spatial specificity if the signal freely 160 
diffuses through the cell.  The fact that cAMP signals can remain membrane-delimited was 161 
first reported by Rich and co-workers [33].  FRET-based cAMP biosensors have provided 162 
direct evidence that cAMP is compartmentized [34,35].  Ample evidence has emerged 163 
since these reports to support the concept that cAMP does not freely diffuse inside cells 164 
[36].  Hydrolysis of cAMP by PDEs, in some cases existing in multiprotein complexes 165 
including receptors and A-kinase anchoring proteins (AKAPs) [4,17], physical barriers to 166 
diffusion by intracellular structures [37] and the buffering effects of PKA [38] all play roles 167 
in limiting the mobility of cAMP (Figure 2).   168 
PDEs, by virtue of their ability to metabolize cAMP, play critical roles the 169 
establishment and maintenance of compartmentized cAMP signaling domains.  Recent 170 
reviews discuss these effects of PDEs in more detail [39,40].  Very few reports have 171 
examined the distinct localization of specific PDE isoforms in the subcellular microdomains 172 
where these cAMP pools operate, and these investigations have focused primarily on 173 





into close association with a recently activated GPCR [42].  PDEs also bind to certain 175 
AKAP isoforms to target their enzymatic activity to specific signaling complexes.  These 176 
types of interactions expand the potential roles for AKAPs in the formation of 177 
macromolecular signal transduction complexes that create cAMP compartments (Figure 178 
2).  Recent work by the group of Baillie and others using cell-permeable peptide disrupters 179 
provided novel insights into the concept of compartmentized cAMP signaling, particularly 180 
focusing on different PDE4 isoforms.  For example, direct interaction between PDE4A5 181 
and the p75 neurotrophin receptor was implicated in extracellular matrix remodeling and 182 
tissue repair, processes potentially important to target fibrinolysis in COPD [43].  Direct 183 
interaction between PDE4D5 and integrin 5 was implicated in endothelial pro-184 
inflammatory functions, processes known to impact obstructive lung diseases [44]. 185 
Disruptor peptides have been of tremendous value to provide proof-of-concept, although 186 
their development into drug-like tools still in its infancy. 187 
 188 
Dynamic alterations of PDE expression in lung diseases: focus on PDE4  189 
The PDE superfamily consists of 11 gene families with more than 21 individual 190 
genes, each with a distinct profile of substrate specificities, molecular structures and 191 
subcellular localizations (Table 1).  PDE4, PDE7 and PDE8 are cAMP-specific; PDE5, 192 
PDE6 and PDE9 are cGMP-specific; PDE1, PDE2, PDE3, PDE10 and PDE11 are dual-193 
specific [4,45].  Intriguingly, we reported recently that PDE family member mRNA levels 194 
exhibit a differential sensitivity to cigarette smoke in nasal epithelium, bronchial epithelium 195 
and lung tissue from patient cohorts [27].  The gene expression of both PDE1A and 196 
PDE11A were decreased in bronchial epithelium and lung tissue.  PDE7A was decreased 197 





epithelium and lung tissue. These data suggest that these PDE isoforms, largely neglected 199 
in current lung research, are of central importance in pathophysiological processes 200 
induced by cigarette smoke, the latter primarily linked to COPD and IPF pathologies [13].   201 
Of note, PDE4D had a contrasting pattern of change (decreased in bronchial 202 
epithelium and increased in lung tissue), implying that this PDE isoform may be subject to 203 
alternative regulation in the different elements of the respiratory tract.  Alternatively, cell 204 
type specific expression of PDE4D and alterations in these cell types may cause the shift 205 
in expression levels during smoke exposure.  We also reported that changes in PDE3A 206 
and PDE4D protein expression were restricted to distinct lung compartments (bronchial 207 
epithelium versus total lung homogenates) [27].  Our findings correlate with the existence 208 
of a unique amino-terminus of the PDE4 family shown to contribute to the generation of 209 
distinct signalling complexes that seem to maintain local cAMP gradients [19,45].  Indeed, 210 
in primary human airway smooth muscle cells PDE4D, to be more precise PDE4D5, is 211 
subject to cAMP-induced upregulation at the level of gene expression, protein expression 212 
and activity [46], implicating this isoform as an important cAMP negative feedback node.  213 
In human airway smooth muscle PGE2 upregulates PDE4D5 expression and leads to pro-214 
asthmatic changes, including β2AR desensitization, reduced cellular cAMP and increased 215 
airway smooth muscle responsiveness to acetylcholine [47].  Moreover, human airway 216 
smooth muscle from asthmatic patients exhibited an increased PDE4D expression and a 217 
subsequent reduction of cAMP production by β2AR agonists [48].  Together these studies 218 
indicate that alterations in spatio-temporal dynamics of cAMP may contribute to key 219 
features of obstructive lung diseases and further points to the necessity to accelerate 220 
research to successfully target PDE4 family subtypes, such as PDE4D, to overcome 221 





such as PDE4A-D, are specifically linked to Gs-coupled receptors and cAMP production 223 
(Table 1).  Targeting PDE4D might increase the therapeutic benefit for patients suffering 224 
from cigarette smoke-related obstructive lung diseases such as COPD and IPF [13].   225 
 226 
Focus on PDE2 and PDE3 as novel players in lung disease 227 
There are several dual-specific PDE isoforms that are important for maintaining the 228 
crosstalk between the cyclic nucleotides cAMP and cGMP.  Of particular interest is PDE3, 229 
also known as cGMP-inhibited cAMP-specific PDE.  PDE3 exhibits a higher affinity and 230 
lower catalytic hydrolysis rate for cGMP compared to cAMP, thus cGMP acts as a 231 
competitive inhibitor and subsequently leads to inhibition of cAMP hydrolysis by PDE3 232 
[49,50].  On the other hand, binding of cGMP to the amino-terminus of the allosteric 233 
regulatory site of PDE2 increases the hydrolysis rate of cAMP by 10-fold, leading to a 234 
profound drop in cellular cAMP [51,52].  Recent research identified PDE3A as a novel anti-235 
inflammatory target in allergic airway inflammation [53], and as shown for PDE4s, a subset 236 
of PDE3s are specifically linked to Gs-coupled receptors and thus cAMP (Table 1).  In 237 
addition to these interesting features, PDE2 is known to localize in mitochondria and linked 238 
to cardiac and lung injury models [54,55] (Figure 2).  Lung mitochondrial dysfunction, 239 
linked to metabolic dysregulation and metabolic reprogramming [56,57], is caused by air 240 
pollution primarily originating from diesel burning automotive engines and it is envisioned 241 
as a primary cause for lung dysfunction [58-60].  Distinct groups of people are more 242 
susceptible to the health effects of air pollution.  Of particular concern are elderly, children 243 
and people with pre-existing obstructive lung diseases, specifically the groups suffering 244 
from exacerbations [14-16].  Several types of pollutants are released during diesel fuel 245 





hydrocarbons [58-60].  In primary murine tracheal epithelial and airway smooth muscle 247 
cells polycyclic aromatic hydrocarbons reduce cellular cAMP production by β2AR agonists 248 
[61].  Such studies correlate air pollution-induced mitochondrial dysfunction with symptoms 249 
of asthma, COPD and IPF.  Future studies should focus on targeting and stabilizing 250 
subcellular microdomain-specific PDEs to overcome the current limitations in PDE-based 251 
therapies of these obstructive lung diseases.  252 
 253 
Focus on PDE8 as novel player in lung disease 254 
While the cAMP signaling community has largely focused on PDE3 and PDE4 255 
isoforms, other PDEs capable of regulating cAMP levels are encoded in the human 256 
genome.  PDE8A, known as an IBMX-insensitive PDE, is expressed in human airway 257 
smooth muscle cells [62].  This PDE isoform localizes in lipid rafts and specifically 258 
regulates cAMP signaling stimulated by ß2AR with no effect on cAMP signaling stimulated 259 
by PGE2 ([62] and Figure 2). Inhibition of PDE8 may make an advantaged therapeutic 260 
approach since this isoform is not widely expressed in the body and it does not regulate 261 
global cAMP signaling [63].  Specific inhibitors of PDE8, particularly those with proven 262 
pharmacokinetic or safety profiles in animal studies and/or clinical trials, do not exist.  More 263 
work is needed to determine if PDE8 inhibition would provide a therapeutic benefit, but it is 264 
tempting to speculate that it will be particularly effective in combination with ß2AR agonists. 265 
 266 
Conclusions and Future Perspectives 267 
Other than the few reports outlined above, the localization of PDE isoforms in 268 
specific cAMP compartments is unknown.  We and others have postulated that some 269 





localized (Figure 2).  It is further likely that some PDE isoforms regulate a specific signaling 271 
complex in a contextuall manner by moving to a location based on particular stimuli [64]. 272 
Lung fibroblasts provide evidence for this type of regulation.  PGE2, an important 273 
endogenous regulator of lung fibroblasts, displays diminished cAMP responses following 274 
chronic exposure to PGE2.  Our recent data show that PGE2 pretreatment induces 275 
expression of PDE3A, 4B and 4D but that similar treatment with ß2AR agonist only induced 276 
expression of PDE4D [64].  This indicates that EP2 receptors induce qualitatively different 277 
signals than ß2AR despite both coupling to increases in cAMP.  Moreover, the induction of 278 
PDE expression by PGE2 pretreatment reduced cAMP signaling by EP2 receptors but had 279 
no effect on cAMP responses stimulated by ß2AR.  The logical conclusion from these 280 
results is that the induced PDE isoform (likely PDE4B) selectively participates in EP2R 281 
signaling complexes and is excluded from the compartment where ß2AR act.  This highly 282 
specific regulation by one PDE isoform provides an opportunity for new therapeutics that 283 
are more effective with fewer adverse effects.  The fact that broad PDE inhibitors have 284 
enjoyed some clinical success, such as the PDE3 family inhibitor cilostazol and the PDE4 285 
family inhibitor roflumilast, should provide motivation to develop small molecules that are 286 
more selective.  Other approaches for disrupting the complexes where PDE isoforms act 287 
are also possible, as recently reviewed by Blair and Baillie [40] and outlined in detail 288 
above. 289 
Obstructive pulmonary diseases continue to represent leading causes of morbidity 290 
and mortality.  Current bronchodilatory treatments for asthma and COPD leverage cAMP 291 
signaling.  The fact that roflumilast, a PDE4 inhibitor, is an effective add-on therapy for 292 
COPD and asthma shows the importance of the cAMP pathway and the utility of 293 





entire PDE family, such as PDE3 or PDE4, will have numerous effects based on the 295 
widespread expression of these isoforms in many cells and tissues.  Therapeutics that 296 
specifically inhibit limited PDE isoforms, such as PDE3A or PDE4D, will likely enjoy greater 297 
clinical benefits with fewer adverse effects.  Furthermore, certain lung pathologies may 298 
alter PDE expression or localization, causing degradation of cAMP signals to be distorted.  299 
As discussed above, many lung pathologies show altered PDE expression upon exposure 300 
to cigarette smoke.  Such changes would mean the current therapies can’t reach full 301 
therapeutic potential in some patients, but they may also provide therapeutic opportunities 302 
if highly specific inhibitors can be developed to target upregulated PDE isoforms in the 303 
critical cell type and avoid inhibition of other isoforms.   304 
In addition to improving specificity of PDE inhibitors, more research into how 305 
specific PDE isoforms play key roles in distinct subcellular compartments is needed. As 306 
discussed above, PDE isoforms PDE3A, PDE4D and PDE8A are differentially expressed 307 
in distinct lung compartments.  It is likely that other isoforms also have specific localization.  308 
It is our thesis that inhibiting a specific PDE isoform that resides in a distinct locale would 309 
increase intracellular cAMP signaling that couples to a subset of all possible effects of 310 
cyclic nucleotides.  This targeted action would have more specific therapeutic effects but 311 
would also boost the effectiveness of existing therapies.  To reach these goals we need to 312 
fully define the molecules in each cAMP signaling microdomain (including GPCR, AC 313 
isoforms, AKAPs and PDEs), characterize the cellular functions that each microdomain 314 
regulate, and understand the role each one plays in lung pathophysiology.  Targeting of 315 
subcellular cAMP domains using a variety of cAMP sensors has been achieved [35] and 316 
the use of peptide disruptors has provided the proof-of-concept of therapeutic approaches 317 





cAMP signaling microdomains and the PDE isoforms therein should then provide impetus 319 
to develop new drugs with PDE isoform selectivity. 320 
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Figure Legends 335 
Figure 1. PDE inhibition in obstructive lung diseases. Pulmonary diseases such as 336 
COPD, asthma and IPF are characterized a certain degree of airway obstruction, chronic 337 
inflammation and airway remodeling. Global PDE inhibition increases cyclic nucleotide 338 
signaling and therefore provides therapeutic benefit.  However, the widespread expression 339 
of PDEs in all types of lung cells causes broad inhibition of a family of isoforms and 340 
eventually also leads to unwanted side effects.  Specific inhibitors of single PDE isoforms, 341 
particularly those acting specifically in particular subcellular signaling microdomains, have 342 
the potential to be more effective and specific. See text for further detail. 343 
 344 
Figure 2. PDEs facilitate formation and maintenance of cAMP signaling 345 
compartments.  Individual PDE isoforms are expressed in discrete subcellular locations 346 
where they regulate cyclic nucleotide signaling in specific signaling compartments.  Some 347 
of these specific findings are illustrated here.  Understanding the microdomains where these 348 
PDEs are expressed and the cellular functions they regulate can lead to more specific 349 
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